<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=217082&amp;fmt=gif">

MD Biosciences Blog

2015 Recap|Clinical Diagnostics & Translational Research

Posted by MD Biosciences

Find me on:
on Dec 17, 2015 5:57:36 PM

As we wind down to years end, we at MD Biosciences would like to thank everyone, especially our collaborators, for making this year a success. We have undergone significant growth that we expect to continue throughout the upcoming year.

New Developments and Highlights

A significant achievement for MD Biosciences is the addition of our clinical diagnostics testing services. We have received Clinical Laboratory Improvement Amendments (CLIA) accreditation and implemented the quality management systems for CLIA bolstering our Good Laboratory Practices (GLP) quality system. We have made a significant investment in instrumentation to support diagnostics testing with the cobas LC480 DX, QuantStudio DX and MACSQuant flow cytometer. These platforms combined with our extensive in house expertise allow us to offer both in vitro diagnostic (IVD) assays as well as laboratory-developed assays (LDAs). Furthermore, our expanded capabilities permit a wider range of custom molecular (nucleic acids and proteins), cell-based and immunology assays for clinical studies. Our CLIA services supports translation of preclinical results to the clinic.

As we are continually interested in developing new models to reflect the human condition, we are pleased to say that we are currently in the final stages of developing new in vivo cancer services that will include syngeneic cancers such as orthotopic and subcutaneous cancer models. Syngeneic tumors represent optimal models for immunotherapy drug development and are a platform that is at the forefront of cancer drug research. Our scientists have extensive backgrounds in syngeneic cancer research as well as experience in transplantable, spontaneous and transgenic cancers.

New developments in our inflammation services include models of fibrosis as well as the incorporation of gut microbiome research in with our current service offerings.  After attending inflammation conferences such as the World Inflammation Conference in Boston, we recognize the growing interest in the microbiome and its role in many inflammatory diseases and we are taking strides to integrate this with our many inflammatory models.

We are also developing in vitro culturing systems for peripheral and central neural cells. This will allow us to address mode of action questions in models such as diabetic neuropathy.

 In the area of pain research, we have developed the mouse nerve cuff and crush models for peripheral nerve injury. These models compress or crush the sciatic nerve to produce a more consistent pain with less variability than other rodent models of peripheral nerve injury (PNI). Furthermore, we continue to compliment our large animal offerings in pig neuropathic pain and wound healing through publications and use of new clinically translatable tools.


As a testament to our dedication to research, MD Bioscience’s own chief scientist, Sigal Meilin, has been a principle author of two publications this year in the area of pig translational pain research. Dr. Meilin’s first publication, Peripheral Neuritis Trauma In Pigs: A Neuropathic Pain Model in the Journal of Pain, demonstrates that the pain response in pigs closely mimics human pain behavior. Her second paper, Prolonged Analgesic Effect of prf-108 and prf-110 on Post-Operative Pain in Pigs, was recently accepted by Journal of Pain and Therapy and explores the potential of using the post operative pain pig model for the development of a new topical treatment for post operative pain. Sigal has presented her work at multiple conferences, including an oral presentation at the Congress of the European Academy of Neurology held in Berlin, NeuPSIG in France as well as a poster at the Society for Neurology in Chicago this year. 

Future Directions

In the new year, we expect to continue the development of our pig translational models. These models will continue to grow in importance for our clients in response to the ongoing regulatory landscape. We will continue to expand our clinical diagnostic and molecular biology services as well as grow our in vivo cancer division as we continue to customize our services to satisfy our client needs. 

Contact us to hear how we can assist you with your research needs!


Topics: Pain, Inflammation, Neuro/CNS, post-operative pain, cancer/tumor, Microbiome, Biomarkers, CLIA, Neuropathy